CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
预防儿童 ALL 接受 CD19 CAR-T 细胞治疗后的复发：移植与增强型 CAR-T 细胞的作用
英文原题：Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells.
查看英文原题
Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD19特异性嵌合抗原受体（CAR）T细胞疗法已成为治疗复发/难治性B细胞急性淋巴细胞白血病（B-ALL）儿童的重要方案。但尽管初始缓解率超过80%，只有40%至50%的患者能获得持久缓解。本综述总结CD19 CAR-T 治疗后达到微小残留病阴性完全缓解的儿童患者，巩固性造血细胞移植在疾病管理中的作用及现有认识。此外，本文回顾增强CD19 CAR-T 效应功能的策略，重点讨论如何提高细胞持留并防止CD19阴性B-ALL原始细胞出现。
展开英文摘要原文
CD19-specific chimeric antigen receptor (CAR) T-cell therapy has become an integral part of our treatment armamentarium for pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
However, despite initial remission rates of greater than 80%, durable remission occurs in only 40% to 50% of patients. In this review we summarize our current knowledge of the role of consolidative hematopoietic cell transplantation in the management of pediatric patients who achieved a minimal residual disease-negative complete response post CD19 CAR T-cell therapy.
In addition, we review approaches to enhance effector function CD19 CAR T cells, focusing on how to improve persistence and prevent the emergence of CD19- B-ALL blasts.
论文信息
- 作者
- Talleur AC、Naik S、Gottschalk S
- 单位
- Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN.
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Hematology. American Society of Hematology. Education Program2023 Dec 8
- 原文标识
- PubMed 38066941 · DOI 10.1182/hematology.2023000424
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →